Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

Anna Collén, PhD

Project Leader VEGF Project at AstraZeneca

Profile

Anna Collén holds a PhD in Biochemistry at Lund University and joined AstraZeneca in 2001 recruited as a molecular and cell biologist. Before joining AZ Anna spent time at a small biotech in Copenhagen, ALK with antigen production for immunization of humans and one of the world leading technology institutes, VTT in Helsinki, Finland with large scale protein production in collaboration with biotech Genencore, US.  Anna has held a number of increasingly senior positions within Therapy Areas early science units, IMED Discovery Sciences, GMD, Operations and IMED Pharmaceutical Sciences.

In 2011, Anna was appointed as a Director of Reagent and Assay Development (RAD) Department of Discovery Sciences. The RAD department, Anna was heading focuses on collaborative research to provide a diverse range of technical and translational activities in early phase of discovery including, protein production, cell supplies such as primary human cells, stem cells and iPS, transgenic mice models and in vitro and cell based assay development.  In this role Anna successfully established the Advanced Cell Lab which has been the center of excellence for the stem cell initiatives of AZ globally. Additionally, she has been responsible to lead the global phenotypic project portfolio for AstraZeneca from a Discovery Science perspective.

In 2015, Anna was appointed as a Project Director in the Pharmaceutical Development organization in the late state drug development phase for AstraZeneca as part of GMD, today Operations. In this role she has been focusing on drug products and delivery systems for different modalities, both small molecules and new modalities for both the early and the late stage projects like AZD4076, Epanova combinations and Crestor. She has also been part of important in-licensing activities such as the Ionis and APT therapeutics strategic agreement for CVMD. Anna is now enjoying her role as the CMC TA Head for CVMD portfolio in Pharmaceutical Sciences. On her private time, she loves out-door activities and have her own chain saw, like to do clay pigeon shooting and hunting.

Anna Collén, PhD's Network

Agenda Sessions